业绩表现与财务指引 - 第三季度调整后每股收益为0.87美元 营收为166.5亿美元 均超出市场预期[2] - 公司第二次上调并收紧全年盈利指引 将摊薄后每股收益区间从2.90-3.10美元上调至3.00-3.15美元[1] - 公司重申全年营收指引为610亿至640亿美元[1] 产品与业务动态 - 血液稀释剂Eliquis销售额增长22%至20.2亿美元 需求强劲[2] - 心血管疗法需求复苏为公司业绩提供支撑[1][2] - 公司持续进行成本削减并推出新产品 同时业务多元化以应对新冠疫苗和抗病毒药物销售减弱的影响[1][2] 公司与行业环境 - 公司涉及与Metsera相关的诉讼 包括诺和诺德未经邀约收购引发的法律纠纷 此前公司与收购目标达成73亿美元协议[2] - 公司与美国政府达成协议 通过降低医疗保险药品价格以换取三年关税减免 此举为政策能见度提供更大确定性[2]

Key Takeaways Pfizer's Q3 adjusted EPS of $0.87 beat estimates but fell 18% year over year.Revenues dropped 6% to $16.7B, hurt by lower Comirnaty and Paxlovid sales.Pfizer reaffirmed revenue outlook and lifted 2025 EPS guidance to $3.00-$3.15.Pfizer (PFE) reported third-quarter 2025 adjusted earnings per share of 87 cents, which comprehensively beat the Zacks Consensus Estimate of 66 cents per share. Earnings declined 18% year over year.Adjusted EPS includes an acquired in-process R&D charge of 20 cents per ...

Pfizer (NYSE:PFE) Q3 2025 Earnings Call November 04, 2025 10:00 AM ET Company ParticipantsAkash Tewari - Global Head of Biopharmaceutical ResearchChris Schott - Managing DirectorMohit Bansal - Managing Director and Co-Head of Therapeutics ResearchAlex Hammond - Director and Head of TherapeuticsFrancesca DeMartino - SVP and Chief Investor Relations OfficerAamir Malik - Chief U.S. Commercial Officer and EVPDave Risinger - Senior Managing DirectorVamil Divan - Managing DirectorGeoff Meacham - Managing Director ...

For the quarter ended September 2025, Pfizer (PFE) reported revenue of $16.65 billion, down 5.9% over the same period last year. EPS came in at $0.87, compared to $1.06 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $16.6 billion, representing a surprise of +0.3%. The company delivered an EPS surprise of +31.82%, with the consensus EPS estimate being $0.66.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how the ...

Pfizer (NYSE:PFE) Q3 2025 Earnings Call November 04, 2025 10:00 AM ET Speaker2Good day, everyone, and welcome to Pfizer's third-quarter 2025 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DiMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.Speaker0Good morning and welcome to Pfizer's earnings call. I'm Francesca DiMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank yo ...

felton-nyc / Flickr Quick Read Pfizer beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected. Shares of PFE gapped up roughly 12.6% in pre-market trading on the Big Pharma company’s strong Q3 financials and revised EPS guidance. Some investors get rich while others struggle because they never learned there are two completely different strategies to building wealth. Don’t make the same mi ...

Skip to content S&P 500 6,791.80 -1.03% Dow Jones 47,085.60 -0.57% Nasdaq 100 25,649.20 -1.39% Russell 2000 2,441.33 -1.45% FTSE 100 9,660.60 -0.55% Nikkei 225 51,378.70 -2.19% Home >Investing >Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (November 2025) Shares of Pfizer (NYSE: PFE)Â lost 9.90% over the past month after gaining 10.02% the month prior. The stock's year-to-date loss now stands at 7.33%. Over the past year, PFE has fallen by 11.17%. The recent rally in the Big Pharma stock c ...

辉瑞Q3营收166.5亿美元，同比下降6%，主要受新冠产品需求下滑拖累。辉瑞预计全年调整后每股收益3-3.15美元，此前预计2.9-3.1美元，因其非新冠 业务增长抵消整体营收滑坡。 辉瑞Q3营收由去年同期的177亿美元降至166.5亿美元，同比下降6%，主要受新冠产品（Paxlovid和Comirnaty）需求下滑拖累。尽管如此，公司上调 了其全年盈利预测，因其非新冠业务增长抵消整体营收滑坡。 公司在财报中宣布，与特朗普政府达成一项历史性协议，通过直接采购平台提供大幅折扣，换取关税豁免和长期业务的确定性。然而，其进军利润丰厚 的减肥药市场的雄心正面临挑战，在一项关键的收购交易中，辉瑞已针对竞争对手诺和诺德和目标公司Metsera提起诉讼。 4日，辉瑞公布Q3财报： 按业务划分： 第三季度营收166.5亿美元，同比下降6%（运营层面下降7%），市场预估165.9亿美元。 净利润为35.41亿美元，同比下降21%；调整后净利润为49.49亿美元，下降18%。 调整后每股收益0.87美元，同比增长18%，超出市场预期。 全球生物制药业务（Biopharma）第三季度营收163.1亿美元，同比下降6%； Pfize ...

Nov 4, 2025 6:45 AM Eastern Standard Time Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance Share NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising and narrowing guidance for Adjusted diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "I am proud of Pfizer's leadership as the first in our industry to reach an agreement with the U.S ...

Key Points A former pandemic favorite and a lesser-known biopharmaceutical stock both have value to add to a long-term investor's portfolio. Pfizer's growth has slowed from a few years ago, but its tepid stock price is not telling the whole story of this innovative company. Vertex Pharmaceuticals is rapidly expanding its portfolio in the rare-disease drug market, and growing its profits in the process. 10 stocks we like better than Pfizer › The healthcare industry revolves around constant innovat ...